Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas - 1st Edition - ISBN: 9780128148334, 9780128148341

Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas

1st Edition

Volume 1

Editors: Giuseppe Orlando Lorenzo Piemonti Camillo Ricordi Robert J. Stratta Rainer W.G. Gruessner
Hardcover ISBN: 9780128148334
eBook ISBN: 9780128148341
Imprint: Academic Press
Published Date: 8th November 2019
Page Count: 890
Sales tax will be calculated at check-out Price includes VAT/GST
215.00
172.00
275.00
220.00
240.00
192.00
385.41
308.33
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas, Volume 1, sets a new standard in transplant and regenerative medicine. The book details the-state-of-the-art in modern whole pancreas and islet transplantation, including donor selection, immunosuppression, complications, allograft pathology, and more. As regenerative medicine is changing the premise of solid organ transplantation, this volume catalogs the technologies being developed and the methods being implemented to bioengineer or regenerate the endocrine pancreas in order to more effectively treat diabetes. Edited and authored by unparalleled leaders in the field, this new volume argues for a much needed synergy between organ transplantation and regenerative medicine.

Key Features

  • Provides comprehensive and cutting-edge knowledge of whole pancreas and islet transplantation
  • Includes sections that address donor selection, immunosuppression, complications, allograft pathology, and more
  • Offers an update on the progress of regenerative medicine research aimed at beta cells replacement in the treatment of diabetes

Readership

Transplant, regenerative medicine and diabetes investigators, basic scientists, biomedical engineers

Table of Contents

PART A. WHOLE PANCREAS ALLO-TRANSPLANTATION
Section I. Introduction

1. History of Pancreas Transplantation
2. How to build a Pancreas Transplant Program
3. Pathophysiology of Diabetes
4. Epidemiology of Diabetes Mellitus
Section II. The Donor
5. Pancreas Donor Selection
6. Deceased Donor Pancreas Procurement
7. Surgical Techniques for Living Donor Pancreas Transplantation
8. Pancreas Preservation
9. Pancreas Graft Back-Table Surgery Technique
Section III. The Recipient
10. Pancreas Transplant Alone
11. Pancreas After Kidney Transplantation
12. Simultaneous Pancreas-Kidney Transplantation
13. Surgical Techniques for Deceased Donor Pancreas Transplantation
14. Robotic Pancreas Transplantation
15. Pancreas Transplantation in the setting of multivisceral transplantation
16. Imaging in pancreas transplantation
17. Post-Operative Care of the Pancreas Transplanted Patient
18. Immunosuppression for Pancreas Allo-Transplantation
Section IV. Complications after Pancreas Allo-Transplantation
19. Infectious Complications after Pancreas Allo-Transplantation
Paolo Antonio Grossi
20. Medical Complications after Pancreas Transplantation
21. Technical Complications of Pancreas Allo-Transplantation
22. Rejection After Pancreas Transplantation
Section V. Natural History
23. Reversal of Secondary Complications of Type 1 Diabetes (Nephropathy, Neuropathy, Retinopathy, and Cardiopathy)
24. Recurrence of Type 1 Diabetes following Simultaneous Pancreas-Kidney Transplantation
25. Pathological Evaluation of Whole Pancreas Transplants
26. Failure of the Pancreas Allograft
27. Pancreas Retransplantation
Section VI: State of the Art of Pancreas Transplantation
28. The Current State of Pancreas Transplantation in the USA – A Registry Report
29. Trends in Pancreas Transplantation in the United States
30. Experimental pancreas transplantation
31. Pancreas Transplantation:  Current Issues, Unmet Needs and Future Perspectives
PART B. ISLET ALLO-TRANSPLANTATION
Section I. Introduction and Indications

32. Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia
33. Eligibility of Patients with Type 1 Diabetes for Islet Transplantation Alone
34. Islet versus Pancreas Transplantation in Nonuremic Patients with Type 1 Diabetes
35. Simultaneous Islet-Kidney (SIK) and Islet After Kidney Transplantation (IAK)
36. Pancreatic islet transplantation in cystic fibrosis:  lung and islet transplantation
37. Combined Liver and Islet Transplantation in Hepatogenous Diabetes, Cluster Exenteration and Cirrhosis with Type 1 Diabetes
Section II. Donor Selection
38. Evolving approaches to organ allocation for whole pancreas versus islet transplantation
39. Living donors
40. Pancreatic Islet Isolation from Donation After Circulatory Death Pancreas
Section III. Islet Isolation
41. Factors Related to Successful Clinical Islet Isolation
42. Pancreas and Islet Preservation
43. Collagenases in Pancreatic Islet Isolation
44. Predicting the Function of Islets after Transplantation
Section IV. Outcomes after Allogenic Pancreatic Islet
45. Metabolic and Endocrine Evaluation of Islet Transplant Function
46. Procedure-Related and Medical Complications In and After Intraportal Islet Transplantation
47. Secondary Complications of Diabetes
Section V. Current Clinical Results
48. Treating diabetes with islet transplantation: lessons learnt from the Nordic network for clinical islet transplantation
49. UK's nationally funded integrated islet transplant program
50. Type 1 Diabetes transplanted with allogenic islets within the Swiss-French GRAGIL Network
51. Primary graft function and long-term outcome of islet allotransplantation: the Lille experience
52. Treating diabetes with islet transplantation: Lessons from the Milan experience
53. Treating Diabetes with Islet Transplantation: Lessons from the University of Miami
54. Treating Diabetes with Islet Cell Transplantation: Lessons from the Edmonton Experience
Section VI. Monitoring of Allogeneic Islet Grafts
55. Immune monitoring of allogenic islets
56. Markers for Βeta Cell Loss
57. In Vivo Quality Control of Human Islets in the Immunodeficient Mouse to Predict Islet Function in Man: a retrospective study in 87 clinical transplants
Section VII. Immunomodulatory Technologies Applied to Islet Transplantation
58. Progress toward islet transplantation tolerance
59. Anti-inflammatory Strategies to Enhance Islet Engraftment and Survival
60. Islet Immunoisolation by Macroencapsulation
61. Islet Immunoisolation by Microencapsulation
62. Recurrence of Type 1 Diabetes After Beta Cell Replacement
Section VIII. Cellular Therapies in Preclinical and Clinical Islet Transplantation
63. T regulatory cell therapy in preclinical and clinical pancreatic islet transplantation
64. Cellular Therapies in Preclinical Clinical Islet Transplantation: Mesenchymal Stem Cells
65. Alternative transplantation sites for islet transplantation

 

Details

No. of pages:
890
Language:
English
Copyright:
© Academic Press 2020
Published:
8th November 2019
Imprint:
Academic Press
Hardcover ISBN:
9780128148334
eBook ISBN:
9780128148341

About the Editor

Giuseppe Orlando

Giuseppe Orlando, MD, PhD, Marie Curie Fellow, is an Associate Professor and a kidney and pancreas transplant surgeon scientist at the Wake Forest University School of Medicine, in Winston Salem, USA. His research aims at developing platforms for the bioengineering and regeneration of transplantable organs, and at developing therapies to enhance the innate ability of the human body to repair itself after damage. His literature output aims at bridging organ transplantation to regenerative medicine.

Affiliations and Expertise

Section of Transplantation, Wake Forest University Baptist Medical Center Medical Center Boulevard Winston-Salem, NC, USA

Lorenzo Piemonti

At the San Raffaele Scientific Institute (Milan, Italy) Lorenzo Piemonti serves as Director of Diabetes Research Institute and Director of Human Islet Transplantation Program. He also serves as Head of the Beta Cell Biology Unit (Diabetes Research Institute), Director of Human Islet Processing Facility, and coordinator of European Consortium for Islet Transplantation that has been providing Human beta Cell Products for research across state barriers in Europe since 2000. He also serves as Professor in Endocrinology at University “Vita Salute San Raffaele” of Milan and as Honorary Visiting Professor at Vrije Universiteit of Brussel. His area of expertise is mainly focused on diabetes and pancreatology. In particular he has large experience about diabetes and pancreatic cancer. He had in the past studied the role of innate immunity in islet cell biology (especially in the human model of islet transplantation in type 1 diabetes recipient) and in pancreatic cancer biology (especially the role of chemokines and chemokine receptor system in inducing leukocytes infiltration). More recently, his research interests includes beta cell replacement, immune tolerance induction strategies, dendritic cell biology, stem cells. He currently serves as section Editor of Cell Transplantation-the Regenerative Medicine Journal and of Current Diabetes Reports, as editorial board of Acta Dibetologia, as Councilor of the International Pancreas and Islet Transplantation Association (IPITA) of The Transplantation Society (TTS), as member of the National Committee for Food Safety (2018-2021, Italian Ministry of Health) and previously (2011-2017) as member of the European Pancreas and Islet Transplantation Association (EPITA) committee of European Society for Organ Transplantation (ESOT). Lorenzo Piemonti authored more than 200 original articles published in peer-reviewed journals surveyed in PubMed. h-index (December 2018): 43 Web of Science; 47 Scopus; 53 Google Scholar. Considering the period 2001-2018 Lorenzo Piemonti authored a total of 165 original articles published in peer-reviewed journals for an impact factor of 918.344 (mean impact factor: 5.566)

Affiliations and Expertise

IRCCS Ospedale San Raffaele, Director of Diabetes Research Institute and Director of Human Islet Transplantation Program, Milan, Italy

Camillo Ricordi

Camillo Ricordi holds the Stacy Joy Goodman Chair in Diabetes Research. He is Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, Microbiology and Immunology and Director of the Diabetes Research Institute (www.diabetesresearch.org ) and the Cell Transplant Program at the University of Miami. After developing the method for human pancreatic islet isolation, he led the team that performed the first series of successful clinical islet allotransplants to reverse diabetes. He is currently serving as Chairperson of the NIH funded Clinical Islet Transplantation (CIT) Consortium, which standardized cell manufacturing protocols in North America and Europe and just completed the first multicenter FDA Phase III trial of islet transplantation in the US. He is currently Editor-in-Chief of CellR4 (www.cellr4.org) and serves as Founding Chairman of The Cure Alliance (www.thecurealliance.org) and of the Diabetes Research Institute Federation (www.diabetesresearch.org). In 2018 Ricordi was inducted into the National Academy of Inventors for contributing outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society. That same year he was ranked as the #1 world expert in transplantation of insulin producing cells for treatment of diabetes, among over 4,000 physicians, surgeons and scientists evaluated. In 2019 Ricordi was appointed to the Supreme Council of Health (Consiglio Superiore di Sanita) by the Italian Ministry of Health. Ricordi also serves as President of the Board of ISMETT (Mediterranean Institute of Transplantation and Advanced Therapies; http://www.ismett.edu), and was appointed President of Fondazione Ri.MED (http://www.fondazionerimed.eu) by the Italian Prime Minister, for the 2013-2017 term. Ricordi was founding president of the Fondazione Cure Alliance ONLUS and of The Cure Alliance (www.thecurealliance.org) and Chairman of the Diabetes Research Institute Federation (http://www.diabetesresearch.org/Research-Collaboration), coordinating and promoting cure focused research at over 24 leading institutions worldwide, while further developing Telescience platform technologies to eliminate geographic barriers to scientific collaboration. These initiatives now allow scientists and project teams from around the world to synergize efforts and work together like if they are in the same physical space (https://www.corriere.it/cronache/19_febbraio_05/consiglio-superiore-sanita-nomine-7d42c47e-293e-11e9-950e-d545297d98ec.shtml). Dr. Ricordi has been awarded 27 patents, has >1,000 scientific publications, >40,000 citations and a 95 H-index.

Affiliations and Expertise

Director Diabetes Research Institute and the Cell Transplant Program, University of Miami Florida, USA

Robert J. Stratta

Robert J. Stratta, MD, is Professor and Jesse H. Meredith Chair in Transplant Surgery and Director of Transplantation at Wake Forest Baptist Health, which is currently one of the largest kidney and pancreas transplant centers in the US. He also has a cross-appointment as a Professor both in Urology and with the Wake Forest Institute of Regenerative Medicine. He accepted this appointment in October 2001 following many years as Professor of Surgery and Director of Pancreas Transplantation at the University of Nebraska Medical Center and as Professor of Surgery at the University of Tennessee, Memphis. After earning his B.S. degree at the University of Notre Dame, Dr. Stratta received his M.D. degree from the University of Chicago-Pritzker School of Medicine and trained in General Surgery at the University of Utah. He then completed a transplant clinical and research fellowship at the University of Wisconsin-Madison. He is co-author of 6 books, 39 book chapters, 731 abstracts, 102 online commentaries, 423 oral presentations, and 439 peer-reviewed articles dealing predominantly with transplantation. He has accumulated more than $9 million in career research funding. He has been active in medical school, surgical resident, and transplant fellow education since 1988; is a member of 25 medical societies; three editorial and physician review boards each; and numerous local, regional, and national committees including United Network for Organ Sharing (UNOS) activities since 1988. His areas of research interest and expertise include kidney and pancreas allocation and transplantation, immunosuppressive strategies, organ donation and preservation, and expanded criteria donors. He is Past President of the Executive Board of Directors of Carolina Donor Services and was recently Councillor of UNOS Region 11 and a member of the UNOS Board of Directors. He has lectured worldwide on kidney and pancreas transplantation, has performed more than 2000 transplants in his career, is board certified in General Surgery, and has been selected as one of the Best Doctors in America since 1993, one of America's Top Surgeons since 2004, and is currently listed as one of America’s Top Doctors and the Patients’ Choice Award.

Affiliations and Expertise

Wake Forest Baptist Health, Department of Surgery, Section of Transplantation, Winston-Salem, NC, USA

Rainer W.G. Gruessner

Dr. Rainer W.G. Gruessner, MD, FACS, FICS is the Clarence and Mary Dennis Professor of Surgery and Chairman of the Department of Surgery at SUNY Downstate Medical Center in Brooklyn, New York. Dr. Gruessner received his medical degree from the School of Medicine, Johannes-Gutenberg-Universität, in Mainz, Germany. He completed his doctoral thesis summa cum laude and obtained the German PhD equivalent (Habilitation) from the Philipps University, in Marburg, Germany. He completed his General Surgery training at the same institution. He received post-graduate training in Germany, Japan, and Minnesota. From 1987-1989, he completed a fellowship in Transplantation Surgery at the University of Minnesota. Dr. Gruessner spent his early academic career at the University of Minnesota (1991-2007) where he quickly rose through the academic ranks to full professor. During this time he held multiple leadership positions (Vice-Chair of Surgery, Vice-Chief of Transplantation, Director of Intestinal Transplant, Co-Director of Pancreas and Liver Transplant). During this time he made many significant contributions to the field of transplantation including the development of new surgical techniques for intestinal, pancreas, and liver transplants. He has edited two textbooks on transplantation, one surgical textbook, written more than 90 textbook chapters and contributed more than 300 manuscripts to the peer-reviewed surgical literature. Dr. Gruessner has been an invited speaker at over 150 institutions and meetings worldwide. Prior to joining SUNY Upstate Medical University as the Chief of Transplantation (2015-2017), Dr. Gruessner served as the Chairman of Surgery at the University of Arizona from 2007 to 2014. Dr. Gruessner has obtained intramural and extramural grant funding. Dr. Gruessner has an established track record in building strong, nationally reputed surgical programs; performing all types of abdominal transplants (kidney, pancreas, liver, and bowel) in adults and children, both from deceased and living donors; mentoring many surgical residents and fellows; overseeing residency and fellowship programs; and conducting basic science research with intra- and extramural funding. Dr. Gruessner is a member of over 20 national and international professional societies, has organized several international congresses, is an editorial board member for about 10 journals and has served on many professional and societal committees.

Affiliations and Expertise

Department of Surgery, State University of New York, SUNY-Downstate Medical Center, Brooklyn, NY, USA

Ratings and Reviews